← Back to Screener
Sutro Biopharma, Inc. (STRO)
Price$34.58
Favorite Metrics
Price vs S&P 500 (26W)310.74%
Price vs S&P 500 (4W)53.98%
Market Capitalization$572.90M
All Metrics
Book Value / Share (Quarterly)$0.53
P/TBV (Annual)0.69x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.78%
Cash Flow / Share (Quarterly)$-20.84
Price vs S&P 500 (YTD)194.95%
Net Profit Margin (TTM)-186.45%
EPS (TTM)$-22.55
10-Day Avg Trading Volume0.29M
EPS Excl Extra (TTM)$-22.55
Revenue Growth (5Y)19.13%
EPS (Annual)$-22.49
ROI (Annual)-509.99%
Net Profit Margin (5Y Avg)-193.80%
Cash / Share (Quarterly)$16.48
Revenue Growth QoQ (YoY)-21.35%
ROA (Last FY)-109.93%
Revenue Growth TTM (YoY)65.18%
EBITD / Share (TTM)$-22.27
ROE (5Y Avg)-137.55%
Operating Margin (TTM)-154.53%
Cash Flow / Share (Annual)$-20.84
P/B Ratio13.02x
P/B Ratio (Quarterly)3.45x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)5.02x
Net Interest Coverage (TTM)-14.06x
ROA (TTM)-79.02%
EPS Incl Extra (Annual)$-22.49
Current Ratio (Annual)2.01x
Quick Ratio (Quarterly)1.94x
3-Month Avg Trading Volume0.16M
52-Week Price Return558.67%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.84
P/S Ratio (Annual)5.59x
Asset Turnover (Annual)0.59x
52-Week High$34.58
Operating Margin (5Y Avg)-189.28%
EPS Excl Extra (Annual)$-22.49
CapEx CAGR (5Y)-24.97%
26-Week Price Return317.63%
Quick Ratio (Annual)1.94x
13-Week Price Return164.58%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.01x
Enterprise Value$514.765
Revenue / Share Growth (5Y)55.85%
Asset Turnover (TTM)0.42x
Book Value / Share Growth (5Y)5.00%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-186.55%
Cash / Share (Annual)$16.48
3-Month Return Std Dev80.05%
Net Income / Employee (TTM)$-1
ROE (Last FY)-509.99%
Net Interest Coverage (Annual)-5.34x
EPS Basic Excl Extra (Annual)$-22.49
P/FCF (TTM)26.50x
Receivables Turnover (TTM)16.28x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-22.55
Receivables Turnover (Annual)16.28x
ROI (TTM)-223.84%
P/S Ratio (TTM)5.59x
Pretax Margin (5Y Avg)-189.95%
Revenue / Share (Annual)$12.06
Tangible BV / Share (Annual)$3.77
Price vs S&P 500 (52W)524.03%
Year-to-Date Return198.88%
5-Day Price Return20.15%
EPS Normalized (Annual)$-22.49
ROA (5Y Avg)-50.31%
Net Profit Margin (Annual)-186.45%
Month-to-Date Return38.82%
Cash Flow / Share (TTM)$-2.80
EBITD / Share (Annual)$-22.27
Operating Margin (Annual)-154.53%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-135.52%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-22.55
P/TBV (Quarterly)1.33x
P/B Ratio (Annual)3.40x
Pretax Margin (TTM)-186.55%
Book Value / Share (Annual)$5.40
Price vs S&P 500 (13W)162.19%
Beta1.56x
P/FCF (Annual)51.52x
Revenue / Share (TTM)$11.73
ROE (TTM)-223.84%
52-Week Low$5.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.75
3.81
3.81
3.94
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
STROSutro Biopharma, Inc. | 5.59x | 65.18% | — | — | $34.58 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Sutro Biopharma is a clinical-stage biopharmaceutical company developing protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF cell-free protein synthesis platform. Lead programs include STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers, with additional candidates in development.